

Medical Immunization Exemption Certificate For Use in Healthcare Facilities

Section 1: Healthcare Facility and Worker Information									
Name of Healthcare Facility	Street Ad	ddress		City	ZIP Co	de	Phone		
Healthcare Worker Name				Date of Birth					
Healthcare Worker Name				Date of Birth					
Street Address		City		ZIP Code Phone					
Section 2: For Healthcare Prov	ider Use Only - P	rovide name, a	ddres	s, vaccine contra	indicatio	n(s), signa	ture, and date.		
Name of Lagithagus Duggidan	Ctroot A	d due o o		City	ZID Ca		Dhana		
Name of Healthcare Provider Street Addr		acress		City ZIP Code Phone		Phone			
I certify that due to the contraindic	ation(s) checked be	slow the above na	amod in	dividual is exempt fr	om rocoivi	na the requi	red vaccine(s)		
2. The contraindication(s) marked b									
American Academy of Pediatrics							guideiiries,		
7 monoan 7 toddon y o'r Galdinoc	(7 train) gardonnico,	or vaccine packa	igo irioc	Trinotraditorio. (Orio	OK WITOTO	арріїосьіо)			
□ Influenza □ N	MR 🗆	Varicella	П	Tdap □ H	lepatitis	в п	I COVID-19		
				•	раши-				
Contraindications				*Precautions			141 141 4		
☐ Serious allergic reaction (e.g., a		previous		☐ Current moderate or severe acute illness, with or without					
vaccine dose (General for all vaccines)				fever (General for all vaccines)					
☐ Serious allergic reaction (e.g., anaphylaxis) to a vaccine				☐ MMR – Recent administration of an antibody-					
component (General for all vaccine		certain chronic		containing blood product, history of thrombocytopenia or thrombocytopenic purpura, need for tuberculin skin					
□Influenza (LAIV) – Pregnancy, immunosuppression, certain chronic medical conditions (e.g., cochlear implant), receipt of specific				testing or interferon gamma release assay testing,					
antivirals 48 hours before vaccination (i.e., amantadine, rimantadine,				personal or family history of seizures					
zanamivir, or oseltamivir. Avoid use of these antivirals until 14 days				☐ Varicella – Recent administration of an antibody-					
after vaccination.)				containing blood product					
☐ MMR –Severe immunodeficiency, due to any cause, including				☐ Tetanus toxoid-containing vaccine, Influenza –					
HIV; pregnancy				Guillain-Barre syndrome history within six weeks after a					
☐ Varicella – Substantial suppression of cellular immunity, including				previous dose					
severely immunocompromised with HIV; pregnancy				☐ Influenza – Sev	_		00 1		
□Tdap – Encephalopathy (e.g., coma, decreased level of consciousness,				☐ COVID-19 – History of multi-inflammatory syndrome					
prolonged seizures) not attributable to another identifiable cause				☐ COVID-19 – History of myocarditis or pericarditis					
within seven days of administration of previous dose of DTP, DTaP, or Tdar COVID-19 (Novavax, Janssen) – Known allergy to polysorbate				following an mRNA or Novavax COVID-19 vaccine					
LICOVID-19 (NOVAVAX, Janssen) -	Dolysolbale		☐ COVID-19 – History of anaphylaxis after any vaccine other than COVID-19 vaccine or after any injectable						
			therapy (i.e., intramuscular, intravenous, or subcutaneous						
			vaccines or therapies [excluding subcutaneous						
			immunotherapy for allergies, i.e., "allergy shots"]); People						
			with a history of a non-severe, immediate (onset less than						
		four hours) allergic reaction after a dose of one type COVID-19 vaccine have a precaution to the same COVID-19 vaccine; People with an allergy-related			of one type of				
					••				
				contraindication to one type of COVID-19 vaccine have a					
				precaution to the other types of COVID-19 vaccines					
				☐ Tdap – History of arthus-type hypersensitivity reactions			•		
				after a previous dose of tetanus toxoid-containing vaccine; Defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid containing vaccine.					
									☐ Tdap – Progressive or unstable neurologic disorders;
				Defer Tdap vaccination until a treatment regimen has been					
							established and the condition has stabilized.		

Healthcare Provider Signature	Date					
*Conditions listed as precautions should be reviewed as well as recommended actions per CDC. Benefits of, and risks for, administering a specific vaccine to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered.						
and for more information on vaccine excipients (<u>www.cdc.gov/vaccines/recs/vac-admin/contration</u>						
Vaccine package inserts and CDC recommendations for these vaccines should be consulted for additional information on vaccine-related contraindications and pr						

The identifiable information provided by the healthcare worker to the facility shall not be disclosed to any third party without the written authorization of the healthcare worker, pursuant to the Rhode Island Confidentiality Healthcare Information Act, RI General Laws chapter 5-37.1. Do not send a copy of this form to the Rhode Island Department of Health. Only non-identifying information aggregated by the facility shall be reported to the Rhode Island Department of health for statistical purposes.

2022